Molecular Pathology Laboratory
                        Understanding disease
                                One signal at a time....

Al-Mulla
Lab

Diagnostic
Division

 Patients'
information		 Doctors'
information		 Students' Material

Literature

 Contact us
     TESTS OFFERED  Breast
cancer		  Colorectal cancer  Ewing's sarcoma Oligodendroglioma Cytogenetics    

Diagnostic Division

 

  


We have invested heavily in state-of-the-art technologies to offer our patients "tailored" medical care. We believe that every patient is unique, therefore similar diseases can behave differently in different patients. The tests we apply to the diseased tissues allow us to administer the proper treatment for each patients. A concept known as individualized therapy.
  Fluorescent in situ
hybridization for Breast cancer		 Breast cancer: This is the commonest cancer in woman. Amplification of Her-2/neu oncogene on chromosome 17 is associated with aggressive breast cancer. However, These cancers are amenable to treatment with monoclonal antibody to HER-2 protein receptor. The monoclonal antibody is known as Herceptin and is given to patients with breast cancer, which have amplified Her-2 oncogene.
We use FDA approved systems to report on  the Her-2 gene status accurately in less than 2 days/case. Such quick and accurate reporting is important when time is so valuable.
 
   

Fluorescent in situ
hybridization for Ewing's sarcoma

  

Ewing's sarcoma: This is one of the most aggressive cancers and accurate diagnosis is vital. The chromosome 11:22 translocation if present helps in the differential diagnosis.

 

 

  

Microarrays

  

Genetic profiling of cancers and genetic disorders such as mental retardation

 

 
  Fluorescent in situ
hybridization for bladder cancer		 Urovision  a non-invasive highly sensitive test for the early detection of Bladder Cancer. The test is designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21.
 
 

Copyright al-mulla.org©
2007